| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/26/2012 | US20120022043 Pyrazolopyrimidine jak inhibitor compounds and methods |
| 01/26/2012 | US20120022042 Carbocyclic glyt1 receptor antagonists |
| 01/26/2012 | US20120022030 Tetracyclic Lactame Derivatives |
| 01/26/2012 | US20120022015 Method of treatment and supplement |
| 01/26/2012 | US20120022013 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| 01/26/2012 | US20120022012 Glycosylated Acetaminophen Pro-Drug Analogs |
| 01/26/2012 | US20120022007 Method and composition for modulating canonical wnt pathway using folate and inositol |
| 01/26/2012 | US20120022001 Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle |
| 01/26/2012 | US20120021992 Methods for improving neurological outcome after neural injury and neurodegenerative disease |
| 01/26/2012 | US20120021991 Use of a botulinum neurotoxin to alleviate various disorders |
| 01/26/2012 | US20120021990 Peptides useful as dual caspase-2/-6 inhibitors and their biological applications |
| 01/26/2012 | US20120021979 GLP-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction |
| 01/26/2012 | US20120021973 Peptides for Treatment of Obesity |
| 01/26/2012 | US20120021971 Functional Food Product Comprising Heat Shock Protein or a Hydrolysate Thereof |
| 01/26/2012 | US20120021470 Chimeric PUFA Polyketide Synthase Systems and Uses Thereof |
| 01/26/2012 | US20120021079 Garcinia Mangostana L. and Iridoid Based Formulations |
| 01/26/2012 | US20120021074 P2x3, receptor antagonists for treatment of pain |
| 01/26/2012 | US20120021070 Chlorite Formulations and Methods of Preparation and Use Thereof |
| 01/26/2012 | US20120021057 Once-daily oral ir/cr pramipexole formulation |
| 01/26/2012 | US20120021053 Controlled release and taste-masking oral pharmaceutical composition |
| 01/26/2012 | US20120021051 Zaleplon gastroretentive drug delivery system |
| 01/26/2012 | US20120021040 Therapeutic agent for spinal cord injuries |
| 01/26/2012 | US20120021039 Expression of neuropeptides in mammalian cells |
| 01/26/2012 | US20120021017 N-phenylacetamide derivatives, which inhibit the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them |
| 01/26/2012 | US20120021016 Novel dioxo-imidazolidine derivatives, which inhibit the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them |
| 01/26/2012 | US20120020994 Multivalent, drying resistant, evolution-based vaccines |
| 01/26/2012 | US20120020991 Prodomain modulators of adam 10 |
| 01/26/2012 | US20120020987 MHC-Less cells |
| 01/26/2012 | US20120020981 Anti-IL6/IL-6R Antibodies and Methods of Use Thereof |
| 01/26/2012 | US20120020975 Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) |
| 01/26/2012 | US20120020956 Activation of sodium potassium atpase |
| 01/26/2012 | US20120020954 Methods of predicting clinical course and treating multiple sclerosis |
| 01/26/2012 | US20120020936 Treatment of neurodegenerative disease using placental stem cells |
| 01/26/2012 | US20120020933 Method of nerve repair with amnion and chorion constructs |
| 01/26/2012 | US20120020931 Therapeutic encapsulated embryonic stem cells and mesenchymal stromal cells |
| 01/26/2012 | US20120020929 Methods and compositions relating to neuronal cell and tissue differentiation |
| 01/26/2012 | US20120020916 Use of il-12 and il-12 antagonists in the treatment of autoimmune diseases |
| 01/26/2012 | US20120020911 Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same |
| 01/26/2012 | US20120020881 Triaryl-sulphonium compounds, kit and methods for labeling positron emitting isotopes |
| 01/26/2012 | US20120020833 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
| 01/26/2012 | US20120018333 Reducing Side Effects of Tramadol |
| 01/26/2012 | US20120017924 Coated nicotine-containing chewing gum, manufacture and use thereof |
| 01/26/2012 | DE102010027595A1 Clinical application of adenosine derivative, preferably (dihydroxyphenyl)ethyl-amino-purin-9-yl-(hydroxymethyl)oxolane-diol, for reducing body temperature during impending ischemia of brain vessels, which occur during heart attacks |
| 01/26/2012 | CA2808432A1 Tricyclic proteasome activity enhancing compounds |
| 01/26/2012 | CA2806258A1 Fused heterocyclic compound and application thereof |
| 01/26/2012 | CA2806069A1 Methods of intravenous administration of glyburide and other drugs |
| 01/26/2012 | CA2806062A1 Topical treatment of neuropathic pain and methods of diagnosis |
| 01/26/2012 | CA2806017A1 Methods of use of cyclic amide derivatives to treat schizophrenia |
| 01/26/2012 | CA2805985A1 Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia |
| 01/26/2012 | CA2805963A1 A method of treating attention deficit hyperactivity disorder |
| 01/26/2012 | CA2805943A1 A method of treating alzheimer's disease |
| 01/26/2012 | CA2805904A1 Methods of use cyclic amide derivatives to treat sigma receptor-mediated disorders |
| 01/26/2012 | CA2805745A1 Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease |
| 01/26/2012 | CA2805693A1 Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders |
| 01/26/2012 | CA2803006A1 Methods and compositions for treatment of multiple sclerosis |
| 01/25/2012 | EP2409977A1 Amide derivative |
| 01/25/2012 | EP2409976A1 Glycine transporter inhibitor |
| 01/25/2012 | EP2409703A1 Treatment with alpha7-selective ligands |
| 01/25/2012 | EP2409152A1 Methods for modulating circadian rythms |
| 01/25/2012 | EP2408778A1 N-[(6-aza-bicyclo[3.2.1]oct-5-yl)-aryl-methyl]-heterobenzamide derivatives, preparation thereof, and therapeutic use of same |
| 01/25/2012 | EP2408775A1 Oxidated derivatives of triazolypurines useful as ligands of the adenosine a2a receptor and their use as medicaments |
| 01/25/2012 | EP2408772A1 Compounds |
| 01/25/2012 | EP2408767A2 Amide derivatives as neuropeptide y5 receptor ligands |
| 01/25/2012 | EP2408763A2 Derivatives of n-ý(2-aza-bicycloý2.1.1¨hex-1-yl)-aryl-methyl¨-heterobenzamide, preparation thereof and application of same in therapeutics |
| 01/25/2012 | EP2408760A1 Thiophenyl sulfonamides for the treatment of alzheimer's disease |
| 01/25/2012 | EP2408757A1 Novel alpha-(n-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production a novel alpha-(n-sulfonamido) acetamide compound incorporating deuterium as inhibitor of beta amyloid peptide production |
| 01/25/2012 | EP2408756A1 Alpha-(n-benzenesulfonamido)cycloalkyl derivatives |
| 01/25/2012 | EP2408747A1 Substituted pyridine derivatives and their medical use |
| 01/25/2012 | EP2408743A1 Carbamate derivatives in particular for the treatment of neurological disorders |
| 01/25/2012 | EP2408460A1 Sceletium extract and uses thereof |
| 01/25/2012 | EP2408450A1 A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| 01/25/2012 | EP2408446A1 Use of pharmaceutical compositions containing mesembrenone |
| 01/25/2012 | EP2408434A1 Treating alzheimer's disease and osteoporosis and reducing aging |
| 01/25/2012 | EP2408304A1 Cgrp receptor antagonists |
| 01/25/2012 | EP2408303A1 Morphinan derivatives with high oral bioavailability |
| 01/25/2012 | EP1879591B1 Use of azapaullones for preventing and treating pancreatic autoimmune disorders |
| 01/25/2012 | EP1804804B1 3-[4-(DIBENZO[b,f][1,4]OXAZEPIN-11-YL)-PIPERAZIN-1-YL]-2,2-DIMETHYL PROPANOIC ACID FOR USE IN THE TREATMENT OF SLEEP DISORDERS |
| 01/25/2012 | EP1781631B1 Diarylmethyl piperazine derivatives, preparations thereof and uses thereof |
| 01/25/2012 | EP1670453B1 Amino acid based compositions for the treatment of pathological conditions distinguished by insufficient mitochondrial function |
| 01/25/2012 | EP1503773B9 Hepatoprotective activity of 2 -p-hydroxybenzoylmussaenosidic acid |
| 01/25/2012 | EP1440157B1 Methods and means for producing proteins with predetermined post-translational modifications |
| 01/25/2012 | EP1434597B1 USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY |
| 01/25/2012 | EP1432991B1 Identification and isolation of somatic stem cells and uses thereof |
| 01/25/2012 | EP1351707B9 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays |
| 01/25/2012 | EP1310494B1 PPAR (delta) ACTIVATORS |
| 01/25/2012 | CN1891260B Corydalis decumbens extract, and its preparing method and use |
| 01/25/2012 | CN102333863A Non-embryonic stem cells and uses thereof |
| 01/25/2012 | CN102333781A Tricyclic pyrazolopyrimidine derivative |
| 01/25/2012 | CN102333778A Salt of tetrahydrotriazolopyridine derivative and crystal thereof |
| 01/25/2012 | CN102333769A Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof as hif activators |
| 01/25/2012 | CN102333766A Carboxamide compounds and their use as calpain inhibitors |
| 01/25/2012 | CN102333764A Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same |
| 01/25/2012 | CN102333762A Ethanamine compounds and their use for treating depression |
| 01/25/2012 | CN102333569A Amine or amino alcohols as glyt1 inhibitors |
| 01/25/2012 | CN102333532A Drug abuse deterrent, methods and compositions |
| 01/25/2012 | CN102333531A Treatment of dyskinesia related disorders |
| 01/25/2012 | CN102333530A Ceramide-analogous metabolites |
| 01/25/2012 | CN102333524A Methods of administering (4ar, 1oar)-i-n-propyl-i, 2,3,4a7 s1io7 ioa-octahydrobenzo [g] quinoline-6,7-diol and related compounds across the oral mucosa, the nasal mucosa or the skin and pharmaceutical compositions thereof |
| 01/25/2012 | CN102329799A Seventeen rat source miRNAs and corresponding miRNA precursors and antisense oligonucleotides thereof |
| 01/25/2012 | CN102329735A Method for preparing curvularin and indolizidine alkaloid and application |